Regeneron Pharmaceuticals demonstrates exceptional profitability characteristics that distinguish it within the biotechnology sector. The company's net margin of 29.65% substantially exceeds typical biotech operating profiles, while its gross margin of 85.7% reflects robust pricing power across its therapeutic portfolio. Systematic screening highlights an ROE of 14.32% coupled with an ROA of 11.07%, indicating efficient capital deployment in a capital-intensive industry.

The balance sheet structure reveals considerable financial stability. With a debt-to-equity ratio of just 0.09 and a current ratio of 4.13, the model indicates strong liquidity positioning that supports ongoing R&D investments and pipeline advancement. The current price of $762.63 trades within 7% of the 52-week high of $821.11, following a 3.29% single-day advance, while the beta of 0.18 signals minimal correlation to broader market volatility—an atypical characteristic for growth-oriented biotechnology names.

Key strengths from fundamental screening:

• Valuation metrics appear measured relative to profitability, with a P/E ratio of 17.49 and P/S of 5.19 supported by EPS of $41.03
• Book value per share of $295.71 provides tangible asset backing, yielding a P/B of 2.6
• Revenue growth of 5.92% YoY indicates steady commercial expansion despite a maturing product base

Risk factors identified: EPS growth of 4.4% YoY trails revenue expansion, suggesting margin compression or increased operating expenses. The absence of reportable free cash flow per share data limits complete cash generation analysis relative to peers ABBV and AMGN, which typically emphasize cash return metrics in their investor communications.